Literature DB >> 9554993

Neuronal and glial epitopes and transmitter-synthesizing enzymes appear in parallel with membrane excitability during neuroblastoma x glioma hybrid differentiation.

W Ma1, J J Pancrazio, M Coulombe, J Dumm, R Sathanoori, J L Barker, V C Kowtha, D A Stenger, J J Hickman.   

Abstract

The membrane excitability and the presence of neural proteins, including neuronal and glial markers and neurotransmitter-synthesizing enzymes, were examined in parallel while the NG108-15 cell line was maintained in a serum-free medium. Whole-cell recordings in voltage-clamp or current-clamp configurations were used to evaluate the membrane excitability, and immunostaining was done with a panel of well-characterized antibodies against NSE, NF150, S-100 beta, GFAP, ChAT and TH. Culture for 4 to 10 days led to a striking rise in neurite outgrowth, electrical excitability and expression of neural proteins in type I neuron-like cells, which were of both neuronal and glial character, and expressed both cholinergic and adrenergic traits. After about 2 weeks, type II cells which lack neurite processes began to emerge. The type II cells proliferated, as revealed by BrdU uptake, and gradually overgrew differentiated cell types. They exhibited little or no membrane excitability and absence of immunoreactivity for the neuronal and glial specific proteins tested. These measurements indicate that the presence of these neural proteins at crucial stages of membrane excitability development is an important characteristics of NG108-15 cell differentiation, providing insights into the neural development and the reversible nature of neoplasia in the nervous system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554993     DOI: 10.1016/s0165-3806(97)00208-3

Source DB:  PubMed          Journal:  Brain Res Dev Brain Res        ISSN: 0165-3806


  8 in total

1.  Toxin detection based on action potential shape analysis using a realistic mathematical model of differentiated NG108-15 cells.

Authors:  Dinesh K Mohan; Peter Molnar; James J Hickman
Journal:  Biosens Bioelectron       Date:  2006-02-03       Impact factor: 10.618

2.  Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro.

Authors:  Nidhi Kaushal; Matthew J Robson; Abagail Rosen; Christopher R McCurdy; Rae R Matsumoto
Journal:  Eur J Pharmacol       Date:  2013-12-28       Impact factor: 4.432

3.  Nanoscale Nonlinear dynamic characterization of the neuron-electrode junction.

Authors:  V Thakore; A Behal; P Molnar; D C Leistritz; J J Hickman
Journal:  J Comput Theor Nanosci       Date:  2008-11-01

4.  AC927, a σ receptor ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells.

Authors:  Nidhi Kaushal; Meenal Elliott; Matthew J Robson; Anand Krishnan V Iyer; Yon Rojanasakul; Andrew Coop; Rae R Matsumoto
Journal:  Mol Pharmacol       Date:  2011-11-18       Impact factor: 4.436

5.  An optimization-based study of equivalent circuit models for representing recordings at the neuron-electrode interface.

Authors:  V Thakore; P Molnar; J J Hickman
Journal:  IEEE Trans Biomed Eng       Date:  2012-06-08       Impact factor: 4.538

6.  Analysis of toxin-induced changes in action potential shape for drug development.

Authors:  Nesar Akanda; Peter Molnar; Maria Stancescu; James J Hickman
Journal:  J Biomol Screen       Date:  2009-12

7.  Voltage-gated sodium channel expression and action potential generation in differentiated NG108-15 cells.

Authors:  Jinxu Liu; Huiyin Tu; Dongze Zhang; Hong Zheng; Yu-Long Li
Journal:  BMC Neurosci       Date:  2012-10-25       Impact factor: 3.288

8.  Ion Channel Drugs Suppress Cancer Phenotype in NG108-15 and U87 Cells: Toward Novel Electroceuticals for Glioblastoma.

Authors:  Juanita Mathews; Franz Kuchling; David Baez-Nieto; Miranda Diberardinis; Jen Q Pan; Michael Levin
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.